About PTC Therapeutics
PTC Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, small molecule therapeutics that focus on post-transcriptional control processes. The Company's lead product, Translarna (ataluren), is used for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in ambulatory patients with age of over five years and older. Its programs include Translarna for nonsense mutation cystic fibrosis (nmCF), Translarna for mucopolysaccharidosis type I caused by nonsense mutation (nmMPS I), Translarna for nonsense mutation aniridia, Translarna for nonsense mutation Dravet syndrome/CDKL5, Spinal muscular atrophy (SMA) in collaboration with Spinal Muscular Atrophy Foundation (SMA Foundation) and F. Hoffman-La Roche Ltd and Hoffman- La Roche Inc. (collectively Roche), and Cancer stem cell program (PTC596). It has two compounds in clinical development within the SMA program: RG7800 and RG7916.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: PTCT
- Previous Close: $13.31
- 50 Day Moving Average: $13.65
- 200 Day Moving Average: $10.86
- 52-Week Range: $4.03 - $16.50
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -3.83
- P/E Growth: 0.32
- Market Cap: $446.54M
- Outstanding Shares: 34,165,000
- Beta: 1.38
- Net Margins: -236.68%
- Return on Equity: -90.33%
- Return on Assets: -50.69%
Companies Related to PTC Therapeutics:
- Debt-to-Equity Ratio: 0.69%
- Current Ratio: 5.74%
- Quick Ratio: 5.74%
What is PTC Therapeutics' stock symbol?
PTC Therapeutics trades on the NASDAQ under the ticker symbol "PTCT."
Where is PTC Therapeutics' stock going? Where will PTC Therapeutics' stock price be in 2017?
11 analysts have issued twelve-month price targets for PTC Therapeutics' shares. Their forecasts range from $7.00 to $120.00. On average, they expect PTC Therapeutics' stock price to reach $34.00 in the next twelve months.
When will PTC Therapeutics announce their earnings?
PTC Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, February, 27th 2017.
What are analysts saying about PTC Therapeutics stock?
Here are some recent quotes from research analysts about PTC Therapeutics stock:
Jefferies Group LLC analysts commented, "PTCT reported ~$81M Translarna net sales in 2016 (higher vs. our est of $75M) and guided $105-125M for 2017 sales. The topline data for Translarna Ph3 study in CF continues to be expected in late-1Q17 and the company plans to file NDA in DMD over protest in the US. Additional pipeline in SMA and cancer are progressing on-track." (1/10/2017)
According to Zacks Investment Research, "PTC Therapeutics, Inc. is a biopharmaceutical company. It is focused on the discovery and development of orally administered, small-molecule drugs for genetic disorders, oncology and infectious disease. PTC Therapeutics, Inc. is based in South Plainfield, United States. " (12/9/2016)
Who owns PTC Therapeutics stock?
PTC Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Frontier Capital Management Co. LLC (4.01%), RTW Investments LP (2.92%), Bogle Investment Management L P DE (2.21%), FMR LLC (2.14%), State Street Corp (1.74%) and Numeric Investors LLC (1.66%). Company insiders that own PTC Therapeutics stock include Allan Steven Jacobson, David P Southwell, Mark Elliott Boulding, Mark Rothera, Michael L Kranda, Neil Gregory Almstead, Richard Aldrich, Robert J Spiegel, Shane William Charles Kovacs and Stuart Walter Peltz.
Who sold PTC Therapeutics stock? Who is selling PTC Therapeutics stock?
PTC Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Pinnacle Associates Ltd., Commerzbank Aktiengesellschaft FI and Dimensional Fund Advisors LP.
Who bought PTC Therapeutics stock? Who is buying PTC Therapeutics stock?
PTC Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including RTW Investments LP, Numeric Investors LLC, FMR LLC, Sicart Associates LLC, Orbimed Advisors LLC, Frontier Capital Management Co. LLC, Oxford Asset Management and A.R.T. Advisors LLC.
How do I buy PTC Therapeutics stock?
Shares of PTC Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of PTC Therapeutics stock cost?
One share of PTC Therapeutics stock can currently be purchased for approximately $13.07.